Although most XLAS patients with a typical clinical presentation are diagnosed nowadays with a genetic examination without performing a renal biopsy procedure, atypical, late-onset cases are biopsied, and the ultrastructural abnormalities of GBM suggest the need for genetic testing for the COL4A5 mutation. The gene discussed is COL4A5; the disease is glioblastoma.